Compositions and methods comprising binding proteins for adalimumab
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 3, 2015
Grant Date -
Mar 12, 2009
app pub date -
Aug 27, 2008
filing date -
Aug 28, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully